Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy  by Singh, Steven N et al.
Prevalence and Significance of Nonsustained Ventricular Tachycardia
in Patients With Premature Ventricular Contractions and Heart
Failure Treated With Vasodilator Therapy
STEVEN N. SINGH, MD, SUSAN G. FISHER, PHD, PETER E. CARSON, MD,
ROSS D. FLETCHER, MD, AND THE DEPARTMENT OF VETERANS AFFAIRS CHF STAT INVESTIGATORS
Washington, DC and Hines, Illinois
Objectives. This study sought to determine the prevalence and
significance of nonsustained ventricular tachycardia (NSVT) in
patients with premature ventricular contractions (PVCs) and
heart failure treated with vasodilator therapy.
Background. Heart failure patients with ventricular arrhyth-
mia and NSVT have a significantly increased risk of premature
cardiac death. Recently there has been the question of whether
these arrhythmias are expressions of a severely compromised
ventricle or are they independent risk factors. We, therefore,
determined the prevalence and significance of NSVT in patients
with PVCs and heart failure and on vasodilator therapy.
Methods. Twenty-four hour ambulatory recordings were done
at randomization, at 2 weeks, at months 1, 3, 6, 9 and 12 and then
every 6 months in 674 patients with heart failure and on vasodi-
lator therapy. The median period of follow-up was 45 months
(range 0 to 54).
Results. Nonsustained ventricular tachycardia was present in
80% of all patients. Patients without (group 1) and with (group 2)
NSVT were balanced for variables: age, etiology of heart disease,
New York Heart Association (NYHA) functional class, use of
amiodarone and diuretics and left ventricular diameter by echo-
cardiogram. However, group 1 patients had significantly less
beta-adrenergic blocking agent use and higher ejection fraction
(EF) (p < 0.002 and p < 0.001, respectively). Survival analysis for
all deaths showed a greater risk of death among group 2 patients
(p 5 0.01). Similarly, sudden death was increased in group 2
patients (p 5 0.02, risk ratio 1.8). After adjusting for the above
variables, only EF (p 5 0.001) and NYHA class (p 5 0.01) were
shown to be independent predictors of survival. Nonsustained
ventricular tachycardia showed a trend (p 5 0.07) as an indepen-
dent predictor for all-cause mortality but not for sudden death.
Only EF was an independent predictor for sudden death.
Conclusions. Nonsustained ventricular tachycardia is fre-
quently seen in patients with heart failure and may be associated
with worsened survival by univariate analysis. However, after
adjusting other variables, especially for EF, NSVT was not an
independent predictor of all-cause mortality or sudden death.
These results have serious implications in that suppression of
these arrhythmias may not improve survival.
(J Am Coll Cardiol 1998;32:942–7)
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Numerous studies have shown an independent direct relation-
ship of complex cardiac arrhythmias (repetitive forms) and left
ventricular dysfunction with subsequent mortality (1–5). This
association was demonstrated for both sudden and nonsudden
cardiac death. Recently many attempts have been made to
suppress these arrhythmias with the hope of improving sur-
vival, and all have fallen short of achieving this goal (6–8).
Perhaps the failure to make a positive impact on outcome may
be related to the fact that these arrhythmias are merely
markers of a severely compromised ventricle and that antiar-
rhythmic treatment does not improve survival (9,10). The
purpose of this report is to determine the prevalence and
clinical significance of nonsustained ventricular tachycardia
(NSVT) in patients with heart failure treated with vasodilator
therapy.
Methods
The design of the trial has been described elsewhere (11).
In brief, patients with documented congestive heart failure and
on vasodilator therapy were prospectively randomized to ami-
odarone or placebo. Ambulatory electrocardiogram (ECG)
recordings were obtained at baseline, at 8 weeks, at months 1,
3, 6, 9 and 12 and then every 6 months thereafter. At baseline,
left ventricular ejection fraction (LVEF) was determined by
radionuclide angiography. Deaths and aborted cardiac arrests
were classified in a blinded manner as sudden, nonsudden or
noncardiac.
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Nonsustained ventricular tachycardia was defined as three
consecutive premature beats in a row, at a rate of 100
beats/min. Fast NSVT were those episodes $120 beats/min
while long NSVT was defined as episodes $15 consecutive
premature ventricular contractions (PVCs). Ambulatory re-
cordings were analyzed by a computerized system and arrhyth-
mia density on 10% of all such recordings were hand-counted.
A 90% correlation was considered acceptable. There was an
excess of 90% correlation between the two methods.
Statistics. Baseline demographic data were expressed as
mean and standard deviation values or percentages. The
chi-square test was used to compare differences between
groups for categorical variables, and similarly the t-test was
used for continuous variables. Survival was calculated from
randomization to death or last known follow-up using the
Kaplan-Meier method. The log rank test was used to compare
survival distributions; the risk ratio and respective 95% confi-
dence interval (CI) for each survival comparison is provided.
Using the PHREG procedure from the Statistical Analysis
System (SAS) version 6.12 (SAS Institute, Cary, North Caro-
lina), Cox proportional hazards modeling was conducted to
identify independent prognostic factors. Variables entered into
the model included those which were different between groups
(ejection fraction, left ventricular external dimension [LVED],
PVC density, beta-blocker use) and those previously identified
as potentially associated with survival in similar patient groups
(amiodarone, type of cardiomyopathy, New York Heart Asso-
ciation [NYHA] class and diuretic use). A two-sided alpha
level of 0.05 was considered statistically significant.
Results
Characteristics of patients. There were 666 patients: 142
without (group 1) and 524 with NSVT (group 2) at baseline.
There were no significant differences between the two groups
with respect to age, race, NYHA functional class, presence of
coronary artery disease, atrial fibrillation, hypertension or
diabetes, previous bypass surgery, smoking and alcohol use,
type of cardiomyopathy and use of diuretics, calcium channel
blocking agents or angiotensin-converting enzyme (ACE) in-
hibitors. However, group 2 patients had significantly lower EF,
larger left ventricular internal dimension, higher density of
PVC per hour, and less beta blocker use. Fast NSVT was
present in 82% and long NSVT was observed in 10% of the
patients. Table 1 summarizes these baseline variables. The
median follow-up period was 45 months (range 0 to 54).
NSVT and outcome. Nonsustained ventricular tachycardia
showed an association with increased overall mortality and
sudden cardiac death using a univariate model analysis (Fig. 1).
However, after adjusting for EF, NYHA class, diuretic use,
type of cardiomyopathy, LVED, PVC density and use of beta
blocker or amiodarone, only EF (p 5 0.001) and NYHA
function class (p 5 0.01) were independent predictors of
all-cause mortality. Moreover, the suppression of NSVT by
amiodarone had no effect on total survival nor on sudden
cardiac death. Ejection fraction was the only independent
predictor of sudden cardiac death.
There were no significant differences in all-cause mortality
nor in sudden death mortality in patients with slow NSVT vs.
fast NSVT (Fig. 2). Similarly, there were no differences in the
group with long vs. short NSVT (Fig. 3).
Additional retrospective analyses were done to classify
patients’ NSVT over time. There were 33 study patients in
whom NSVT was never documented on a Holter; there were
162 patients in whom NSVT was documented on every study
Holter; and the remaining 434 patients had NSVT docu-
mented on some of the Holters (ever). Overall mortality and
sudden death rates of those 33 with no documented NSVT
over time were similar to patients having NSVT (ever) (Fig. 4).
In contrast, the overall and sudden death survival of patients
never having VT was significantly better than that of patients
who had persistent (always) VT (Fig. 5). After adjustment for
other baseline variables, the survival related to sudden death
was still not different between groups.
Discussion
Present study. Our findings show that in patients with
PVCs and heart failure and on vasodilator therapy, the pres-
Table 1. Baseline Characteristics
NSVT
No
(n 5 142)
Yes
(n 5 524)
Age 65 6 9 66 6 8
Race (white) 113 (80%) 393 (75%)
Current smokers 35 (25%) 107 (20%)
Current alcohol users 39 (27%) 135 (26%)
Hypertension 91 (64%) 308 (59%)
Ischemic disease 107 (75%) 368 (70%)
Diabetes 53 (38%) 163 (31%)
Calcium-channel blockers 40 (28%) 108 (21%)
ACE inhibitors 132 (93%) 475 (91%)
Diuretics 119 (84%) 466 (89%)
Beta-blockers 13 (9%) 16 (31%)
CABG 37 (26%) 160 (31%)
Amiodarone 76 (54%) 253 (48%)
EF 28 6 7% 25 6 8%*
LVED(Echo) 64 6 11 mm 67 6 9 mm*
NYHA Class II 83 (60%) 281 (55%)
NYHA Class III 1 ? 56 (40%) 228 (45%)
Atrial fibrillation 18 (13%) 85 (16%)
PVC/h 62 6 84 322 6 407*
NSVT
Mean events 99 6 345
Fast ($120 bpm) 426 (82%)
Long ($15 beats) 53 (10%)
*p , 0.01. ACE 5 angiotensin-converting enzyme; CABG 5 coronary artery
bypass graft surgery; EF 5 ejection fraction; LVED(Echo) 5 left ventricular
external dimension as determined by echocardiography; NSVT 5 nonsustained
ventricular tachycardia; NYHA 5 New York Heart Association classification;
PVC/h 5 number of premature ventricular contractions per hour.
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ence of NSVT on ambulatory recordings after adjusting for
other variables, especially EF, is not an independent prognos-
tic risk factor for all-cause mortality and especially for sudden
cardiac death. This is true regardless of the rate or length of
the NSVT runs. This was not only true for presence of NSVT
on baseline recordings, but also for those patients who devel-
oped at least one episode of NSVT on subsequent recordings
when compared to patients with no episode throughout the
study period. Only EF and NYHA functional class indepen-
dently predicted all-cause mortality. Most important, only EF
predicted sudden cardiac death.
Previous studies. Previous trials in patients with left ven-
tricular dysfunction or heart failure have shown that ventricu-
lar arrhythmias are associated with excess total and sudden
cardiac death mortality (1–5). Bigger et al. (1) examined the
relationship among ventricular arrhythmias, left ventricular
dysfunction and mortality in the 2 years after a myocardial
infarction, and in 766 patients there was a definite independent
relationship among PVC frequency, PVC runs and LVEF. The
instantaneous probability of dying in patients with LVEF
,30% and PVC runs was almost seven times greater than in
patients without any of the risk factors. However, it should be
noted that this is in a population with prior myocardial
infarction.
Maggioni et al. (12) in the Gruppo Italiano per lo Studio
della Streptochiansi nell’Infarto Miocardico (GISSI-2) re-
ported the prevalence and prognostic significance of ventricu-
lar arrhythmias after a myocardial infarction in the fibrinolytic
era. While PVC frequency of $10/h independently predicted
total and all-cause mortality, NSVT was not associated with
worsened survival at 6 months after adjusting for other vari-
ables. This was also true for patients with congestive heart
failure (CHF). For patients with fast NSVT ($120 beats/min),
NSVT was still not associated with excess mortality. It is of
interest to note in another trial that after adjusting for other
variables, especially EF, PVC frequency was not predictive of
mortality for patients with prior myocardial infarction in the
1990s (13).
Packer (9) showed a lack of relation between ventricular
arrhythmias and sudden cardiac death. He noted that NSVT is
a marker for hemodynamic and clinical instability and not a
harbinger of sudden death. Moreover, in a large heart failure
study, Massie et al. (10) showed that NSVT was predictive of
cardiovascular mortality but not sudden cardiac death. Non-
sustained ventricular tachycardia on ambulatory ECG had no
independent prognostic value after adjusting for other vari-
ables in the Veterans Administration Heart Failure Trial II
(14). And finally, in the Electrophysiologic Study Versus
Figure 1. Kaplan–Meier estimates of (A) overall and (B) sudden death
mortality according to the presence or absence of nonsustained
ventricular tachycardia (NSVT) and unadjusted for ejection fraction.
Figure 2. Kaplan–Meier estimates of (A) overall and (B) sudden death
mortality according to NSVT rate less than (slow) or greater than
(fast) 120 beats/min. There are no significant differences in either
group.
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Electrocardiographic Monitoring (ESVEM) trial (15), NSVT
at baseline was not predictive of subsequent events.
Szabo et al. (16), on the other hand, examined the relation-
ship between ventricular arrhythmias and outcome in patients
with heart failure. They showed that ejection and presence of
VT after adjustment had statistically prognostic value in pre-
dicting sudden death. By univariate analyses sudden death was
predicted by VT $2 s, VT rate $144 beats/min. Our results
differ perhaps because of patient selection bias. While all our
patients had symptomatic heart failure, only some patients in
Szabo’s study expressed symptoms. Our findings were based on
three times the sample size, minimizing a beta error. More-
over, most of our patients were on ACE inhibitors and other
vasodilator therapy that certainly can affect the mode of death
(17).
Gradman et al. (18) studied 295 heart failure patients and
the data were analyzed according to the presence and absence
of NSVT episodes with respect to mortality. While EF was the
best predictor of total mortality and sudden death, the pres-
ence of NSVT was independently associated with both total
mortality and sudden death (18).
On the other hand, Wilson et al. (19) showed that only
functional class independently predicted cardiac mortality and
ventricular ectopic activity had no relation to prognosis.
Recently, Doval et al. (20), analyzing the data from the
GESICA (Grupo de Estudio de la Sobrevida en al Insuficien-
cia Cardiaca en Argentina) trial, showed that NSVT was an
independent risk factor for increased total and sudden death
mortality. In this study, the presence of NSVT was determined
from ambulatory recordings in 516 patients with heart failure.
Patients with NSVT had an increased relative risk (RR 5 1.69,
CI 1.27 to 2.24, p , 0.002) of dying prematurely. Sudden death
risk was also increased (RR 5 2.77, CI 1.78 to 4.44, p , 0.01).
This excess risk was also seen after adjusting for other variables
and independent of the type (ischemic or nonischemic) of
cardiomyopathy. While GESICA and CHF STAT share many
similarities, there are differences. GESICA included a sicker
population with severely depressed EF or higher NYHA
functional class. Moreover, there were more patients with
nonischemic cardiomyopathy. Our analyses according to types
of cardiomyopathy or use of amiodarone did not change the
results. Unlike GESICA, patients on the CHF STAT study
were required to have $10 PVCs/h at baseline.
Limitations. If it is true that the two major mechanisms for
death in heart failure relate to arrhythmia and pump failure,
then it is quite difficult to understand why the suppression of
Figure 3. Kaplan–Meier estimates of (A) overall and (B) sudden death
mortality according to NSVT length less than (short) or greater than
(long) 15 consecutive beats. There are no significant differences.
Figure 4. Kaplan–Meier estimates of (A) overall and (B) sudden death
rates according to the absence (never) or presence (ever) of NSVT on
any ambulatory recording throughout the study. There are no signifi-
cant differences.
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arrhythmias with a “potentially benign drug” (amiodarone)
and improvement in EF did not lead to an improvement in
mortality (21). Because of the extremely high density of PVCs
in the study groups, it is likely that the risk is already
substantially high in these patients, and the mere presence of
NSVT will not add any further risk. On the other hand, these
arrhythmias could be merely markers for premature death and
that any attempt to suppress them might not improve survival.
The use of beta-blockers in heart failure patients has been
associated with some beneficial effects. The mechanisms of
such benefit is unclear especially since beta-blockers are not
potent suppressors of ventricular arrhythmias. The use of
beta-blockers was very limited in our study. Perhaps it would
have been more difficult to detect any beneficial effect of
amiodarone if there were widespread and balanced use of
beta-blockers. On the other hand, as in the EMIAT trial, the
combined use of beta-blockers and amiodarone in patients
with postmyocardial infarction and left ventricular dysfunction
was much better than beta-blockers alone (22).
Conclusion. Our findings show that the prevalence of
NSVT in CHF is high if the baseline PVC rate is .10/h. The
presence, rate or length of NSVT in this population are not
independent predictors for sudden death or all-cause mortal-
ity. These results have serious implications in that any attempt
to suppress these arrhythmias may not change outcome. We
feel that on the basis of our findings at this time, there is no
need to treat pharmacologically patients on vasodilator ther-
apy with asymptomatic NSVT episodes associated with heart
failure and high density PVCs.
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